

# Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

<https://marketpublishers.com/r/NB7EE021D24EN.html>

Date: July 2020

Pages: 1101

Price: US\$ 2,500.00 (Single User License)

ID: NB7EE021D24EN

## Abstracts

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 62, 51, 1, 8, 175, 70 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Non-Alcoholic Steatohepatitis (NASH) - Overview

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics  
Development

Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 89bio Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ABIONYX Pharma SA, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abivax SA, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abliva AB, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Acquist Therapeutics, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Afimmune Biopharma Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akero Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aldeyra Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Algernon Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aligos Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allysta Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alynlam Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altavant Sciences Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altay Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alteogen Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altimune Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amgen Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Angion Biomedica Corp, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AptaBio Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AptamiR Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Araim Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arkay Therapeutics LLC, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Terns Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TES Pharma SRL, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Theratechnologies Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Thetis Pharmaceuticals LLC, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Thoth Science Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Tiziana Life Sciences Plc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TRACON Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TreeFrog Therapeutics SAS, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Twoxar Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Valin Technologies Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vascular Biogenics Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vectus Biosystems Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Venenum Biodesign LLC, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Venn Therapeutics LLC, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Verlyx Pharma Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vidasym Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viking Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viscient Biosciences LLC, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Visionary Pharmaceuticals Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vivus Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by vTv Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Wave Life Sciences Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Xenexus Pharmaceuticals Pty Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Xfibra Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by XORTX Therapeutics Inc, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by YD Life Science Co, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Yuhan Corp, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zebra Discovery Ltd, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zhejiang Doer Biologics Corp, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, H2 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

89bio Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Therapeutics

AdAlta Ltd

Afimmune Biopharma Ltd

Akero Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Algernon Pharmaceuticals Inc

Aligos Therapeutics Inc

Allergan Ltd

Allysta Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Altavant Sciences Inc

Altay Therapeutics Inc

Alteogen Inc

Altimune Inc

Amgen Inc

Angion Biomedica Corp  
AptaBio Therapeutics Inc  
AptamiR Therapeutics Inc  
Araim Pharmaceuticals Inc  
Arcturus Therapeutics Ltd  
Arkay Therapeutics LLC  
Arrowhead Pharmaceuticals Inc  
ARTham Therapeutics Inc  
Asclepis Pharma Inc  
Asdera LLC  
Assembly Biosciences Inc  
AstraZeneca Plc  
Auransa Inc  
Avaliv Therapeutics Inc  
Avolynt Inc  
Axcella Health Inc  
BBN Cardio Therapeutics  
BerGenBio ASA  
Betagenon AB  
Bioio LLC  
Bird Rock Bio Inc  
Blade Therapeutics Inc  
BLR Bio LLC  
Boehringer Ingelheim International GmbH  
Bristol-Myers Squibb Co  
Buto Biopharma Inc  
Cadila Healthcare Ltd  
Califia Bio Inc  
Can-Fite BioPharma Ltd  
Carmot Therapeutics Inc  
CellCure  
Centaurus Therapeutics Inc  
ChemoCentryx Inc  
ChemomAb Ltd  
Chia Tai Tianqing Pharmaceutical Group Co Ltd  
China NT Pharma Group Co Ltd  
Chipscreen Biosciences Ltd  
ChunLab Inc  
Cirius Therapeutics Inc

CohBar Inc  
Coherus BioSciences Inc  
ConSynance Therapeutics Inc  
Continuum Biosciences Inc  
Corbus Pharmaceuticals Inc  
Corcept Therapeutics Inc  
CSPC Pharmaceutical Group Ltd  
Curadim Pharma Co Ltd  
Cyclerion Therapeutics Inc  
Cytodyn Inc  
D&D Pharmatech Co Ltd  
Daiichi Sankyo Co Ltd  
DeckTherapeutics Inc  
Dicerna Pharmaceuticals Inc  
Dr. Falk Pharma GmbH  
DURECT Corp  
Eli Lilly and Co  
Enanta Pharmaceuticals Inc  
EncuraGen Inc  
Engitix Ltd  
Enyo Pharma SA  
Enzychem Lifesciences Corp  
EpiTracker Inc  
Esperion Therapeutics Inc  
F. Hoffmann-La Roche Ltd  
Fochon Pharmaceutical Ltd  
Forma Therapeutics Inc  
Future Medicine Co Ltd  
Galectin Therapeutics Inc  
Galecto Biotech AB  
Galmed Pharmaceuticals Ltd  
General Regeneratives Shanghai Ltd  
Genfit SA  
GenKyoTex SA  
GI Innovation Co Ltd  
Gilead Sciences Inc  
Gmax Biopharm Ltd  
Guangdong East Sunshine Pharmaceutical Co Ltd  
Guangdong Zhongsheng Pharmaceutical Co Ltd

H. Lundbeck AS  
Hanmi Pharmaceuticals Co Ltd  
HemoShear Therapeutics LLC  
Hepagene Therapeutics Shanghai Inc  
Hepion Pharmaceuticals Inc  
Heprotech Inc  
Hinova Pharmaceuticals Inc  
HK inno.N Corp  
HotSpot Therapeutics Inc  
Ildong Pharmaceutical Co Ltd  
Imago Pharmaceuticals Inc  
ImmuneMed Inc  
Immupharma Plc  
Immuron Ltd  
Indalo Therapeutics Inc  
Inmune Bio Inc  
Innovimmune Biotherapeutics Inc  
Inorbit Therapeutics AB  
Integral Molecular Inc  
Intercept Pharmaceuticals Inc  
INVENT Pharmaceuticals Inc  
InventisBio Inc  
Inventiva  
Ionis Pharmaceuticals Inc  
J2H Biotech  
Jecure Therapeutics Inc  
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd  
Joyce Biotech Corp  
KinDex Pharmaceuticals Inc  
Kinomedica Pty Ltd  
Kirrhos Pharmaceuticals LLC  
KoBioLabs Inc  
Korea United Pharm Inc  
Kowa Co Ltd  
Krisani Bio Sciences Pvt Ltd  
Kyorin Pharmaceutical Co Ltd  
Laekna Therapeutics Shanghai Co Ltd  
LG Chem Ltd  
LifeMax Laboratories Inc

Liminal BioSciences Inc  
Lin Bioscience Inc  
Lipidio Pharmaceuticals Inc  
Lipocine Inc  
LISCure Biosciences Co Ltd  
Lynkogen Inc  
Macrophage Pharma Ltd  
Macrophage Therapeutics Inc  
Madrigal Pharmaceuticals Inc  
Mallinckrodt Plc  
Max Biopharma Inc  
MedPacto Inc  
Melior Pharmaceuticals I Inc  
Merck & Co Inc  
Metabolic Solutions Development Company LLC  
Metabolys SAS  
Metacrine Inc  
MetiMedi Pharmaceuticals Co Ltd  
Micelle BioPharma Inc  
Mina Therapeutics Ltd  
Mitotherapeutix LLC  
Mitsubishi Tanabe Pharma Corp  
Morphic Holding Inc  
Mperia Therapeutics Inc  
MYR GmbH  
Naia Ltd  
Nanjing Sanhome Pharmaceutical Co Ltd  
Nanjing Transthera Biosciences Co Ltd  
Nano Intelligent Biomedical Engineering Corp  
NeuroBo Pharmaceuticals Inc  
Nexel Co Ltd  
NGM Biopharmaceuticals Inc  
Nippon Chemiphar Co Ltd  
Nivarta Inc  
NorthSea Therapeutics BV  
Novartis AG  
Novo Nordisk AS  
NuSirt Biopharma Inc  
Oasis Pharmaceuticals LLC

Onegene Biotechnology Inc  
Oramed Pharmaceuticals Inc  
Osteoneurogen Inc  
Palo BioFarma SL  
Pattern Therapeutics  
PegBio Co Ltd  
Pfizer Inc  
pH Pharma Co Ltd  
Pharmaxis Ltd  
Phenex Pharmaceuticals AG  
Pliant Therapeutics Inc  
Poxel SA  
Promethera Biosciences SA  
Protalix BioTherapeutics Inc  
Proterris Inc  
Protheragen Inc  
PTC Therapeutics Inc  
RadBio  
Redx Pharma Plc  
Regenasome Pty Ltd  
Regulus Therapeutics Inc  
Rejuvenation Technologies Inc  
reMYND NV  
Revive Therapeutics Ltd  
Rhamnopharma Inc  
Ridgeline Therapeutics LLC  
Rivus Pharmaceuticals Inc  
Sagimet Biosciences  
Saje Pharma LLC  
Salix Pharmaceuticals Ltd  
Sanofi  
ScandiCure AB  
Sciwind Biosciences Co Ltd  
Scohia Pharma Inc  
Seal Rock Therapeutics Inc  
Seres Therapeutics Inc  
SFA Therapeutics LLC  
Shanghai Anruite Biological Medicine Technology Co Ltd  
Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd  
Sihuan Pharmaceutical Holdings Group Ltd  
Sineu Pharma Inc  
Sirnaomics Inc  
SparkBioPharma Inc  
SteroTherapeutics LLC  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Sveikatal Inc  
Synlogic Inc  
T3D Therapeutics Inc  
TaiwanJ Pharmaceuticals Co Ltd  
Terns Pharmaceuticals Inc  
TES Pharma SRL  
Theratechnologies Inc  
Thetis Pharmaceuticals LLC  
Thoth Science Inc  
Tiziana Life Sciences Plc  
TRACON Pharmaceuticals Inc  
TreeFrog Therapeutics SAS  
Twoxar Inc  
Valin Technologies Ltd  
Vascular Biogenics Ltd  
Vectus Biosystems Ltd  
Venenum Biodesign LLC  
Venn Therapeutics LLC  
Verlyx Pharma Inc  
Vidasym Inc  
Viking Therapeutics Inc  
Viscient Biosciences LLC  
Visionary Pharmaceuticals Inc  
Vivus Inc  
vTv Therapeutics Inc  
Wave Life Sciences Ltd  
Xenexus Pharmaceuticals Pty Ltd  
Xfibra Inc  
XORTX Therapeutics Inc  
YD Life Science Co  
Yuhan Corp  
Zebra Discovery Ltd

Zhejiang Doer Biologics Corp



## I would like to order

Product name: Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/NB7EE021D24EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NB7EE021D24EN.html>